INJECTABLE
  • Animeal

INJECTABLE

CYTOPOINT 20MG INJ

CYTOPOINT 20MG INJ

By ZOETIS

₹ 4,950
-10% off ₹ 4,950 M.R.P: ₹ 5,500
Tax included. Shipping calculated at checkout.

In Stock

Pack - 1mL
Expires on or after: Feb, 2027
Title

Check Availability

Rapid 3-4 Day Delivery,Tiny Extra Fee!

  • AnimealPet Safe
  • AnimealBest Quality
  • AnimealFast Delivery
  • AnimealSecure Payment
View full details

Cytopoint 20 mg/mL Solution for Injection by Zoetis is a revolutionary, first-in-class caninised monoclonal antibody immunotherapeutic designed to provide targeted, long-lasting relief from the relentless itch associated with atopic dermatitis and allergic dermatitis in dogs. Unlike conventional pharmaceutical treatments that broadly suppress the immune system, Cytopoint works with precision at the molecular level, neutralising the single cytokine most responsible for transmitting itch signals in your canine companion's nervous system. Each 1 mL vial contains 20 mg of Lokivetmab, a biologically engineered antibody structurally identical to the antibodies your dog's own immune system naturally produces. The result is a safe, steroid-free injection that begins controlling allergic itch within one day and delivers sustained relief for four to eight weeks per dose. Animeal is proud to offer Cytopoint 20 mg/mL as part of its commitment to bringing the most advanced, clinically validated dermatological therapies to pet parents who refuse to let their dogs suffer in silence.

Ingredients:

Lokivetmab (Active Ingredient) 20 mg per 1 mL vial: Lokivetmab is a caninised monoclonal antibody (IgG4 subclass) produced via recombinant DNA technology using Chinese Hamster Ovary (CHO) cell expression systems. "Caninised" means the antibody's protein framework is structurally modelled on a canine immunoglobulin scaffold, minimising the risk of anti-drug antibody formation that would occur with foreign protein structures. Lokivetmab targets and binds with high specificity to canine interleukin-31 (IL-31), a pro-inflammatory cytokine secreted predominantly by activated Th2 lymphocytes, mast cells, and eosinophils in allergic skin conditions. When IL-31 binds to its heterodimeric receptor complex (IL-31RA and OSMR) on cutaneous nerve fibres and keratinocytes, it triggers a cascade of downstream JAK-STAT signalling that transmits pruritic (itch) signals to the brain and drives the chronic inflammatory skin cycle of atopic dermatitis. Lokivetmab binds IL-31 before this receptor engagement can occur, completely blocking the itch signalling pathway at its upstream source. Because it acts exclusively on IL-31 without broad immune suppression, the treatment does not compromise the dog's capacity to fight infections, respond to vaccines, or regulate other immune functions.

Histidine and Histidine Hydrochloride Monohydrate (Excipient Buffer): This amino acid buffer pair maintains the formulation's pH at a stable physiological range throughout the shelf life of the product. Histidine acts as an excellent stabilising buffer for monoclonal antibody solutions, protecting the protein structure of Lokivetmab from acid-mediated denaturation or aggregation during storage and administration.

Trehalose Dihydrate (Cryoprotectant and Stabiliser): Trehalose is a disaccharide sugar that stabilises the three-dimensional protein structure of Lokivetmab in liquid formulation by forming hydrogen bonds with the antibody's polar residues, preventing misfolding, aggregation, and loss of bioactivity under thermal or mechanical stress. It serves as a critical formulation excipient for the long-term potency maintenance of the biological product under refrigerated storage.

Methionine (Antioxidant): Methionine is an amino acid included to protect Lokivetmab from oxidative degradation. As an antioxidant excipient in injectable biologics, methionine preferentially oxidises before the antibody's own methionine residues can be oxidised by reactive oxygen species, thereby preserving the binding efficacy and structural integrity of the active protein over the product's two-year shelf life.

Polysorbate 80 (Surfactant): Polysorbate 80 is a non-ionic surfactant that prevents Lokivetmab molecules from aggregating or adsorbing onto the glass vial surfaces or syringe walls during storage and handling. It reduces surface tension at air-liquid and solid-liquid interfaces, maintaining a consistent, particle-free solution that is safe for subcutaneous injection.

Disodium Edetate (Chelating Agent): Disodium edetate (EDTA) chelates trace metal ions in the solution that could otherwise catalyse oxidative degradation of the antibody protein, providing an additional layer of formulation stability.

Water for Injections: Sterile, pyrogen-free water serves as the aqueous solvent base for the solution.

 

Precision Targeting of the Itch Signal at Its Source:
Cytopoint is the first and only veterinary-licensed monoclonal antibody that specifically neutralises canine IL-31, the primary cytokine responsible for transmitting itch signals in allergic skin disease. Unlike antihistamines, corticosteroids, or broad immunosuppressants, it does not generalise across the immune system but instead intercepts the exact molecular message that tells your dog's brain to itch, alleviating pruritus with a level of precision that no previous veterinary dermatology therapy has been able to achieve.

Rapid Onset with Long-Lasting Relief:
Clinical studies have demonstrated that Cytopoint begins reducing itch within 24 hours of a single subcutaneous injection, with sustained relief lasting four to eight weeks per dose in most dogs. This long duration of action means your canine companion can experience weeks of comfort, skin healing, and restored quality of life between veterinary visits, replacing the burden of daily oral medication with a simple, reliable injectable schedule.

Structurally Identical to Your Dog's Own Immune Proteins:
Because Lokivetmab is a caninised antibody, it is biologically and structurally recognised by your dog's immune system as a self-protein rather than a foreign substance. This greatly reduces the risk of treatment-related immune reactions and makes Cytopoint one of the safest long-term treatment options available for managing chronic atopic dermatitis in dogs across all age groups and breeds.

No Pressure on the Liver or Kidneys:
Unlike chemical-based anti-pruritic drugs such as corticosteroids, Cytopoint does not undergo hepatic metabolism or renal clearance as a small-molecule pharmaceutical. As a biologic antibody, it is processed through normal protein catabolism pathways, meaning it does not impose pharmacological burden on your dog's liver or kidneys, making it a particularly valuable option for older dogs or those with concurrent metabolic conditions.

Proven Safety Alongside a Wide Range of Concomitant Medications:
Field safety studies involving hundreds of canine patients confirm that Cytopoint is safely co-administered with a broad range of medications commonly prescribed in atopic dermatitis management, including antiparasitics, antibiotics, antifungals, corticosteroids, allergen-specific immunotherapy, antihistamines, oclacitinib, and cyclosporine. No clinically significant drug interactions have been identified, making it a versatile cornerstone of multimodal dermatological care.

Allows Damaged Skin to Begin Healing:
By eliminating the itch-scratch cycle that perpetuates secondary skin damage, epidermal breakdown, and bacterial superinfection in atopic dogs, Cytopoint creates the physiological quiet that allows inflamed skin to recover. Dogs receiving Cytopoint consistently demonstrate measurable improvements in CADESI (Canine Atopic Dermatitis Extent and Severity Index) scores alongside owner-reported reductions in scratching, licking, and chewing behaviour.

How to Use:

Cytopoint 20 mg/mL must be administered exclusively by a licensed veterinary professional as a subcutaneous (under the skin) injection and is not approved or safe for home administration. The attending veterinarian will determine the appropriate dose and number of vials required based on the dog's body weight, with a minimum recommended dose of 2 mg/kg. For the 20 mg vial presentation, the entire contents of the vial must be aseptically drawn and administered as a single injection. For dogs requiring a combination of vials, the contents of each required vial must be withdrawn into the same syringe; gently invert the loaded syringe three to four times to allow mixing before administration. Avoid excessive shaking or foaming of the solution at all times. Each vial is for single use only and contains no preservative; any unused contents must be inactivated and discarded immediately following opening. Only sterile, new syringes and needles should be used for each administration. Do not sterilise equipment with chemical disinfectants, as residual traces may inactivate the biological product. If vaccines are being administered during the same visit, Cytopoint must be injected at a separate anatomical site on the body. Repeat administration every four to eight weeks as clinically assessed by the attending veterinarian.

Storage Advice:

Store unopened Cytopoint 20 mg/mL in a refrigerator at 2°C to 8°C, stored upright in the original cardboard packaging to protect from light. Do not freeze under any circumstances, as freezing irreversibly damages the biological structure of Lokivetmab and renders the product inactive. Prolonged exposure to temperatures above 8°C or direct sunlight may adversely affect the potency of the solution. Once the vial has been opened, the contents must be used immediately and any remaining product must be discarded; the opened vial cannot be stored or reused. Keep out of the sight and reach of children at all times. Do not use after the expiry date printed on the vial label and outer carton.

About the Brand:

Zoetis traces its roots to 1952 as Pfizer's Animal Health Division, and became the world's first independently publicly traded, standalone animal health company following its landmark 2013 IPO on the New York Stock Exchange, raising USD 2.2 billion and cementing its position as the global leader in veterinary medicine. Headquartered in Parsippany, New Jersey and operating manufacturing and R&D facilities across 28 sites in 11 countries, Zoetis holds the distinction of being the world's largest animal health company by revenue, generating USD 9.3 billion in sales in 2024, and has been repeatedly recognised on Ethisphere's list of the World's Most Ethical Companies. The company's commitment to cutting-edge innovation is exemplified by Cytopoint itself, which represents the first USDA-approved monoclonal antibody therapy specifically developed for a companion animal dermatological condition, emerging from Zoetis's dedicated biologic R&D investment in caninised antibody technology. Zoetis's values of scientific rigour, species-specific precision medicine, and sustainability in animal healthcare align with Animeal's commitment to offering only the most trusted, evidence-backed therapies for your beloved pet. Discover Zoetis today.

Disclaimer:

Please note that while Cytopoint 20 mg/mL is formulated from Lokivetmab, a caninised anti-IL-31 monoclonal antibody, and is appropriate for dogs requiring management of atopic or allergic dermatitis, it is a prescription-only injectable veterinary medicinal product and must not be purchased, stored, or administered without the authorisation and direct supervision of a licensed veterinarian. This product is not indicated for use in cats, other species, or dogs under 3 kg body weight, and its safety in pregnant, lactating, or breeding animals has not been established. Cytopoint manages the symptoms of atopic dermatitis and is not a cure for the underlying allergic condition; allergen identification, trigger avoidance, and concurrent skin infection management remain essential components of a comprehensive atopic dermatitis treatment plan. For dogs with a known history of hypersensitivity to monoclonal antibody preparations, or those presenting with concurrent bacterial skin infections at the time of treatment, consult your veterinarian before initiating Cytopoint therapy. Animeal supports your pet's health and happiness journey but does not replace the advice of a qualified veterinary professional.

Q: Is Cytopoint suitable for all dogs?
Cytopoint is approved for use in dogs of all ages, breeds, and sizes, provided they weigh a minimum of 3 kg. It is not indicated for cats or any other animal species. Dogs that are pregnant, lactating, or used for breeding should only receive Cytopoint following explicit veterinary assessment, as safety data in these groups has not yet been fully established. Breed-specific sensitivities are not a known contraindication, and the product has been evaluated across a diverse canine population in clinical trials.
Q: How often does my dog need a Cytopoint injection?
A single Cytopoint injection delivers itch relief that typically lasts four to eight weeks, and repeat administration is scheduled based on the individual dog's clinical response as assessed by your veterinarian. Some dogs may require monthly injections while others experience relief for the full eight weeks. Your veterinarian will generally schedule a progress review four weeks after the first injection to assess the response and determine the optimal ongoing dosing interval for your canine companion.
Q: How effective is Cytopoint at controlling atopic dermatitis?
In controlled field studies spanning up to nine months, a single dose of Cytopoint at 2 mg/kg produced statistically significant reductions in both owner-assessed pruritus scores (Visual Analog Scale) and veterinarian-assessed skin lesion scores (CADESI-03) compared to placebo. In clinical practice, approximately 60 to 70 percent of dogs show a meaningful improvement following their first injection, with a subset experiencing a full or near-complete resolution of itch. A small proportion of dogs may have a limited or absent response, attributable to the highly targeted nature of IL-31 blockade in the context of a complex, multi-cytokine disease.
Q: Are there side effects or safety concerns associated with Cytopoint?
Cytopoint is exceptionally well-tolerated. In clinical trials, the rate of adverse events in Cytopoint-treated dogs was statistically indistinguishable from that seen in placebo-treated dogs, with no clinically relevant differences in blood chemistry parameters. Rare reports from post-market surveillance include hypersensitivity reactions such as anaphylaxis, facial oedema, or urticaria, as well as isolated neurological signs including seizure and ataxia; these warrant immediate veterinary attention if observed. Because Cytopoint is a biologic and not a chemical drug, it does not impose hepatic or renal pharmacological burden, making it a particularly suitable long-term option for senior dogs or those with organ compromise.
Q: How can I access Cytopoint for my dog through Animeal?
Cytopoint 20 mg/mL is available on Animeal at animeal.in as a veterinary prescription product. As a prescription-only injectable, it will require a valid veterinary prescription before purchase can be fulfilled. Visit animeal website, search for Cytopoint, and our team will guide you through the prescription verification process to ensure your canine companion receives this therapy safely and legally. Animeal's customer support team is available to assist with any product or prescription queries throughout the process.
CYTOPOINT 20MG INJ - Animeal
Rx Required
🚚 FREE delivery on orders above ₹499
10 DaysEasy Returns
100%Authentic
SecurePayments
INJECTABLE

CYTOPOINT 20MG INJ

By ZOETIS
₹ 4,950.00
You save ₹ 550.00 (10%)
MRP ₹ 5,500.00 (Incl. taxes)

In Stock

Size
₹ 4,950.00
MRP ₹ 5,500.00  10% OFF
1
Check Availability

Cytopoint 20 mg/mL Solution for Injection by Zoetis is a revolutionary, first-in-class caninised monoclonal antibody immunotherapeutic designed to provide targeted, long-lasting relief from the relentless itch associated with atopic dermatitis and allergic dermatitis in dogs. Unlike conventional pharmaceutical treatments that broadly suppress the immune system, Cytopoint works with precision at the molecular level, neutralising the single cytokine most responsible for transmitting itch signals in your canine companion's nervous system. Each 1 mL vial contains 20 mg of Lokivetmab, a biologically engineered antibody structurally identical to the antibodies your dog's own immune system naturally produces. The result is a safe, steroid-free injection that begins controlling allergic itch within one day and delivers sustained relief for four to eight weeks per dose. Animeal is proud to offer Cytopoint 20 mg/mL as part of its commitment to bringing the most advanced, clinically validated dermatological therapies to pet parents who refuse to let their dogs suffer in silence.

Ingredients:

Lokivetmab (Active Ingredient) 20 mg per 1 mL vial: Lokivetmab is a caninised monoclonal antibody (IgG4 subclass) produced via recombinant DNA technology using Chinese Hamster Ovary (CHO) cell expression systems. "Caninised" means the antibody's protein framework is structurally modelled on a canine immunoglobulin scaffold, minimising the risk of anti-drug antibody formation that would occur with foreign protein structures. Lokivetmab targets and binds with high specificity to canine interleukin-31 (IL-31), a pro-inflammatory cytokine secreted predominantly by activated Th2 lymphocytes, mast cells, and eosinophils in allergic skin conditions. When IL-31 binds to its heterodimeric receptor complex (IL-31RA and OSMR) on cutaneous nerve fibres and keratinocytes, it triggers a cascade of downstream JAK-STAT signalling that transmits pruritic (itch) signals to the brain and drives the chronic inflammatory skin cycle of atopic dermatitis. Lokivetmab binds IL-31 before this receptor engagement can occur, completely blocking the itch signalling pathway at its upstream source. Because it acts exclusively on IL-31 without broad immune suppression, the treatment does not compromise the dog's capacity to fight infections, respond to vaccines, or regulate other immune functions.

Histidine and Histidine Hydrochloride Monohydrate (Excipient Buffer): This amino acid buffer pair maintains the formulation's pH at a stable physiological range throughout the shelf life of the product. Histidine acts as an excellent stabilising buffer for monoclonal antibody solutions, protecting the protein structure of Lokivetmab from acid-mediated denaturation or aggregation during storage and administration.

Trehalose Dihydrate (Cryoprotectant and Stabiliser): Trehalose is a disaccharide sugar that stabilises the three-dimensional protein structure of Lokivetmab in liquid formulation by forming hydrogen bonds with the antibody's polar residues, preventing misfolding, aggregation, and loss of bioactivity under thermal or mechanical stress. It serves as a critical formulation excipient for the long-term potency maintenance of the biological product under refrigerated storage.

Methionine (Antioxidant): Methionine is an amino acid included to protect Lokivetmab from oxidative degradation. As an antioxidant excipient in injectable biologics, methionine preferentially oxidises before the antibody's own methionine residues can be oxidised by reactive oxygen species, thereby preserving the binding efficacy and structural integrity of the active protein over the product's two-year shelf life.

Polysorbate 80 (Surfactant): Polysorbate 80 is a non-ionic surfactant that prevents Lokivetmab molecules from aggregating or adsorbing onto the glass vial surfaces or syringe walls during storage and handling. It reduces surface tension at air-liquid and solid-liquid interfaces, maintaining a consistent, particle-free solution that is safe for subcutaneous injection.

Disodium Edetate (Chelating Agent): Disodium edetate (EDTA) chelates trace metal ions in the solution that could otherwise catalyse oxidative degradation of the antibody protein, providing an additional layer of formulation stability.

Water for Injections: Sterile, pyrogen-free water serves as the aqueous solvent base for the solution.

 

Precision Targeting of the Itch Signal at Its Source:
Cytopoint is the first and only veterinary-licensed monoclonal antibody that specifically neutralises canine IL-31, the primary cytokine responsible for transmitting itch signals in allergic skin disease. Unlike antihistamines, corticosteroids, or broad immunosuppressants, it does not generalise across the immune system but instead intercepts the exact molecular message that tells your dog's brain to itch, alleviating pruritus with a level of precision that no previous veterinary dermatology therapy has been able to achieve.

Rapid Onset with Long-Lasting Relief:
Clinical studies have demonstrated that Cytopoint begins reducing itch within 24 hours of a single subcutaneous injection, with sustained relief lasting four to eight weeks per dose in most dogs. This long duration of action means your canine companion can experience weeks of comfort, skin healing, and restored quality of life between veterinary visits, replacing the burden of daily oral medication with a simple, reliable injectable schedule.

Structurally Identical to Your Dog's Own Immune Proteins:
Because Lokivetmab is a caninised antibody, it is biologically and structurally recognised by your dog's immune system as a self-protein rather than a foreign substance. This greatly reduces the risk of treatment-related immune reactions and makes Cytopoint one of the safest long-term treatment options available for managing chronic atopic dermatitis in dogs across all age groups and breeds.

No Pressure on the Liver or Kidneys:
Unlike chemical-based anti-pruritic drugs such as corticosteroids, Cytopoint does not undergo hepatic metabolism or renal clearance as a small-molecule pharmaceutical. As a biologic antibody, it is processed through normal protein catabolism pathways, meaning it does not impose pharmacological burden on your dog's liver or kidneys, making it a particularly valuable option for older dogs or those with concurrent metabolic conditions.

Proven Safety Alongside a Wide Range of Concomitant Medications:
Field safety studies involving hundreds of canine patients confirm that Cytopoint is safely co-administered with a broad range of medications commonly prescribed in atopic dermatitis management, including antiparasitics, antibiotics, antifungals, corticosteroids, allergen-specific immunotherapy, antihistamines, oclacitinib, and cyclosporine. No clinically significant drug interactions have been identified, making it a versatile cornerstone of multimodal dermatological care.

Allows Damaged Skin to Begin Healing:
By eliminating the itch-scratch cycle that perpetuates secondary skin damage, epidermal breakdown, and bacterial superinfection in atopic dogs, Cytopoint creates the physiological quiet that allows inflamed skin to recover. Dogs receiving Cytopoint consistently demonstrate measurable improvements in CADESI (Canine Atopic Dermatitis Extent and Severity Index) scores alongside owner-reported reductions in scratching, licking, and chewing behaviour.

How to Use:

Cytopoint 20 mg/mL must be administered exclusively by a licensed veterinary professional as a subcutaneous (under the skin) injection and is not approved or safe for home administration. The attending veterinarian will determine the appropriate dose and number of vials required based on the dog's body weight, with a minimum recommended dose of 2 mg/kg. For the 20 mg vial presentation, the entire contents of the vial must be aseptically drawn and administered as a single injection. For dogs requiring a combination of vials, the contents of each required vial must be withdrawn into the same syringe; gently invert the loaded syringe three to four times to allow mixing before administration. Avoid excessive shaking or foaming of the solution at all times. Each vial is for single use only and contains no preservative; any unused contents must be inactivated and discarded immediately following opening. Only sterile, new syringes and needles should be used for each administration. Do not sterilise equipment with chemical disinfectants, as residual traces may inactivate the biological product. If vaccines are being administered during the same visit, Cytopoint must be injected at a separate anatomical site on the body. Repeat administration every four to eight weeks as clinically assessed by the attending veterinarian.

Storage Advice:

Store unopened Cytopoint 20 mg/mL in a refrigerator at 2°C to 8°C, stored upright in the original cardboard packaging to protect from light. Do not freeze under any circumstances, as freezing irreversibly damages the biological structure of Lokivetmab and renders the product inactive. Prolonged exposure to temperatures above 8°C or direct sunlight may adversely affect the potency of the solution. Once the vial has been opened, the contents must be used immediately and any remaining product must be discarded; the opened vial cannot be stored or reused. Keep out of the sight and reach of children at all times. Do not use after the expiry date printed on the vial label and outer carton.

About the Brand:

Zoetis traces its roots to 1952 as Pfizer's Animal Health Division, and became the world's first independently publicly traded, standalone animal health company following its landmark 2013 IPO on the New York Stock Exchange, raising USD 2.2 billion and cementing its position as the global leader in veterinary medicine. Headquartered in Parsippany, New Jersey and operating manufacturing and R&D facilities across 28 sites in 11 countries, Zoetis holds the distinction of being the world's largest animal health company by revenue, generating USD 9.3 billion in sales in 2024, and has been repeatedly recognised on Ethisphere's list of the World's Most Ethical Companies. The company's commitment to cutting-edge innovation is exemplified by Cytopoint itself, which represents the first USDA-approved monoclonal antibody therapy specifically developed for a companion animal dermatological condition, emerging from Zoetis's dedicated biologic R&D investment in caninised antibody technology. Zoetis's values of scientific rigour, species-specific precision medicine, and sustainability in animal healthcare align with Animeal's commitment to offering only the most trusted, evidence-backed therapies for your beloved pet. Discover Zoetis today.

Disclaimer:

Please note that while Cytopoint 20 mg/mL is formulated from Lokivetmab, a caninised anti-IL-31 monoclonal antibody, and is appropriate for dogs requiring management of atopic or allergic dermatitis, it is a prescription-only injectable veterinary medicinal product and must not be purchased, stored, or administered without the authorisation and direct supervision of a licensed veterinarian. This product is not indicated for use in cats, other species, or dogs under 3 kg body weight, and its safety in pregnant, lactating, or breeding animals has not been established. Cytopoint manages the symptoms of atopic dermatitis and is not a cure for the underlying allergic condition; allergen identification, trigger avoidance, and concurrent skin infection management remain essential components of a comprehensive atopic dermatitis treatment plan. For dogs with a known history of hypersensitivity to monoclonal antibody preparations, or those presenting with concurrent bacterial skin infections at the time of treatment, consult your veterinarian before initiating Cytopoint therapy. Animeal supports your pet's health and happiness journey but does not replace the advice of a qualified veterinary professional.

Q: Is Cytopoint suitable for all dogs?
Cytopoint is approved for use in dogs of all ages, breeds, and sizes, provided they weigh a minimum of 3 kg. It is not indicated for cats or any other animal species. Dogs that are pregnant, lactating, or used for breeding should only receive Cytopoint following explicit veterinary assessment, as safety data in these groups has not yet been fully established. Breed-specific sensitivities are not a known contraindication, and the product has been evaluated across a diverse canine population in clinical trials.
Q: How often does my dog need a Cytopoint injection?
A single Cytopoint injection delivers itch relief that typically lasts four to eight weeks, and repeat administration is scheduled based on the individual dog's clinical response as assessed by your veterinarian. Some dogs may require monthly injections while others experience relief for the full eight weeks. Your veterinarian will generally schedule a progress review four weeks after the first injection to assess the response and determine the optimal ongoing dosing interval for your canine companion.
Q: How effective is Cytopoint at controlling atopic dermatitis?
In controlled field studies spanning up to nine months, a single dose of Cytopoint at 2 mg/kg produced statistically significant reductions in both owner-assessed pruritus scores (Visual Analog Scale) and veterinarian-assessed skin lesion scores (CADESI-03) compared to placebo. In clinical practice, approximately 60 to 70 percent of dogs show a meaningful improvement following their first injection, with a subset experiencing a full or near-complete resolution of itch. A small proportion of dogs may have a limited or absent response, attributable to the highly targeted nature of IL-31 blockade in the context of a complex, multi-cytokine disease.
Q: Are there side effects or safety concerns associated with Cytopoint?
Cytopoint is exceptionally well-tolerated. In clinical trials, the rate of adverse events in Cytopoint-treated dogs was statistically indistinguishable from that seen in placebo-treated dogs, with no clinically relevant differences in blood chemistry parameters. Rare reports from post-market surveillance include hypersensitivity reactions such as anaphylaxis, facial oedema, or urticaria, as well as isolated neurological signs including seizure and ataxia; these warrant immediate veterinary attention if observed. Because Cytopoint is a biologic and not a chemical drug, it does not impose hepatic or renal pharmacological burden, making it a particularly suitable long-term option for senior dogs or those with organ compromise.
Q: How can I access Cytopoint for my dog through Animeal?
Cytopoint 20 mg/mL is available on Animeal at animeal.in as a veterinary prescription product. As a prescription-only injectable, it will require a valid veterinary prescription before purchase can be fulfilled. Visit animeal website, search for Cytopoint, and our team will guide you through the prescription verification process to ensure your canine companion receives this therapy safely and legally. Animeal's customer support team is available to assist with any product or prescription queries throughout the process.
CYTOPOINT 20MG INJ
₹ 4,950.00
₹ 5,500.00  10% OFF

Frequently Asked Questions

Is Cytopoint suitable for all dogs?

Cytopoint is approved for use in dogs of all ages, breeds, and sizes, provided they weigh a minimum of 3 kg. It is not indicated for cats or any other animal species. Dogs that are pregnant, lactating, or used for breeding should only receive Cytopoint following explicit veterinary assessment, as safety data in these groups has not yet been fully established. Breed-specific sensitivities are not a known contraindication, and the product has been evaluated across a diverse canine population in clinical trials.

How often does my dog need a Cytopoint injection?

A single Cytopoint injection delivers itch relief that typically lasts four to eight weeks, and repeat administration is scheduled based on the individual dog's clinical response as assessed by your veterinarian. Some dogs may require monthly injections while others experience relief for the full eight weeks. Your veterinarian will generally schedule a progress review four weeks after the first injection to assess the response and determine the optimal ongoing dosing interval for your canine companion.

How effective is Cytopoint at controlling atopic dermatitis?

In controlled field studies spanning up to nine months, a single dose of Cytopoint at 2 mg/kg produced statistically significant reductions in both owner-assessed pruritus scores (Visual Analog Scale) and veterinarian-assessed skin lesion scores (CADESI-03) compared to placebo. In clinical practice, approximately 60 to 70 percent of dogs show a meaningful improvement following their first injection, with a subset experiencing a full or near-complete resolution of itch. A small proportion of dogs may have a limited or absent response, attributable to the highly targeted nature of IL-31 blockade in the context of a complex, multi-cytokine disease.

Are there side effects or safety concerns associated with Cytopoint?

Cytopoint is exceptionally well-tolerated. In clinical trials, the rate of adverse events in Cytopoint-treated dogs was statistically indistinguishable from that seen in placebo-treated dogs, with no clinically relevant differences in blood chemistry parameters. Rare reports from post-market surveillance include hypersensitivity reactions such as anaphylaxis, facial oedema, or urticaria, as well as isolated neurological signs including seizure and ataxia; these warrant immediate veterinary attention if observed. Because Cytopoint is a biologic and not a chemical drug, it does not impose hepatic or renal pharmacological burden, making it a particularly suitable long-term option for senior dogs or those with organ compromise.

How can I access Cytopoint for my dog through Animeal?

Cytopoint 20 mg/mL is available on Animeal at animeal.in as a veterinary prescription product. As a prescription-only injectable, it will require a valid veterinary prescription before purchase can be fulfilled. Visit animeal website, search for Cytopoint, and our team will guide you through the prescription verification process to ensure your canine companion receives this therapy safely and legally. Animeal's customer support team is available to assist with any product or prescription queries throughout the process.
View All Questions